Philip Newsome (London, UK)

Philip Newsome

(London, UK)
Professor Newsome runs the metabolic services at the Liver Unit at King’s College Hospital London which includes a large multi-disciplinary clinic for patients with non-alcoholic fatty liver disease (NAFLD). He was Chief Investigator on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapies in NAFLD published in the Lancet and the NEJM. He is the Co-ordinating Investigator for several global NAFLD studies and is co-chair of the phase 3 ESSENCE trial of Semaglutide. He chaired the national guidelines for liver transplantation in NAFLD and is the topic advisor for the NICE Guideline Development Group for MASLD. He led the UK multi-stakeholder guideline group on the management of abnormal liver blood tests and led on NAFLD for the recent EASL Lancet Liver Commission. He developed the FAST score for identifying patients with at-risk NASH and also co-led the global nomenclature process that changed the name and definition of NAFLD to metabolic dysfunction-associated steatotic liver disease (MASLD).